BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
UNICEF: More than 100 children killed in Gaza since ceasefire - 26 Well known Ladies' Fragrances On the planet
- 3The most effective method to Distinguish the Best Material Organization in Your Space
- 4What's the new 'Knives Out' mystery about? Everything to know about 'Wake Up Dead Man,' including who's in the cast and what the reviews say.
- 5Electric Vehicles for Eco-Accommodating Driving
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- A definitive Manual for the Over-Ear Earphones
- Relish the World: Notable Caf\u00e9s You Really want to Attempt
- Beating Wellbeing Difficulties: Individual Victories in Health
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- Vote in favor of Your Number one kind of pie
- The 10 Most Persuasive Forerunners in Innovation
- Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- Vote in favor of your Number one method for praising a birthday
